Literature DB >> 8019053

Treatment of hypertension in the presence of coexisting medical conditions.

J Kvasnicka1, J M Flack, R H Grimm.   

Abstract

Treating hypertension reduces morbidity and mortality. Unfortunately, hypertension often exists in patients with other medical conditions. In these patients, the selection of an antihypertensive agent is often influenced by the presence of the coexisting condition. Conversely, the treatment of the coexisting medical condition may be influenced by the presence of hypertension. Given the vast array of antihypertensive medications available today, appropriate treatment of both hypertension and coexisting conditions can be achieved with careful selection of medications. This review discusses factors to consider when treating elderly patients with hypertension with the following coexisting conditions: dyslipidaemia, glucose intolerance, sexual dysfunction, cardiovascular disease, pulmonary disease, renal disease and neuropsychiatric disorders. Hypothyroidism, hyperthyroidism and various states of high cardiac output may cause hypertension. These conditions should be identified, since they are often treatable with subsequent resolution of the hypertension.

Entities:  

Mesh:

Year:  1994        PMID: 8019053     DOI: 10.2165/00002512-199404040-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  30 in total

Review 1.  The heart in hypertension.

Authors:  E D Frohlich; C Apstein; A V Chobanian; R B Devereux; H P Dustan; V Dzau; F Fauad-Tarazi; M J Horan; M Marcus; B Massie
Journal:  N Engl J Med       Date:  1992-10-01       Impact factor: 91.245

2.  Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers.

Authors:  S Yusuf; J Wittes; J Probstfield
Journal:  Am J Cardiol       Date:  1990-07-15       Impact factor: 2.778

3.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

4.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

5.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

6.  Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study.

Authors:  J M Flack; J D Neaton; B Daniels; P Esunge
Journal:  Am J Kidney Dis       Date:  1993-04       Impact factor: 8.860

7.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

8.  Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group.

Authors:  W G Walker; J D Neaton; J A Cutler; R Neuwirth; J D Cohen
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

9.  Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy.

Authors:  J M McLenachan; E Henderson; K I Morris; H J Dargie
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

10.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more
  3 in total

Review 1.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

Review 2.  Hypertension and age-related changes in the heart. Implications for drug therapy.

Authors:  S Isoyama
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

Review 3.  Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.

Authors:  C R Lee; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.